Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

0.63 

-0.03 -4.5%

as of Jun 25 '19

52 Week Range:

0.55 0.95


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Luye Pharma Group Ltd. develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian cancer and treatment for metastatic carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Tiandixin, a product used as an adjuvant therapy for malignant tumors, malignant hydrothorax and ascites, and respiratory infections; and Yitaida for acute promyelocytic leukemia and liver cancer. It also provides Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for the treatment of cancer pain; and Buprenorphine Transdermal Patch for the treatment of chronic pain. In addition, it offers Beixi, an acarbose capsule for diabetes; and Lutingnuo, a reduced glutathione injection for toxicity and injuries caused by ionizing radiation; Beitangning, a pioglitazone hydrochloride capsule to control blood glucose; Nuosen for acute upper digestive tract hemorrhage; and Sailimai for the treatment of diarrhea. Further, it provides Xuezhikang, a lipid adjusting capsule; Maitongna for cerebral edema and swelling caused by trauma; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. Additionally, it distributes, sells, and retails pharmaceutical drugs; manufactures and sells eggs; and provides business and investment consultation, as well as contract research, process development, and manufacturing services. The company also engages in the cultivation of herbs and sales of herbal medicines. The company was founded in 1994 and is headquartered in Yantai, the People's Republic of China. Luye Pharma Group Ltd. is a subsidiary of Luye Life Sciences Group Ltd.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 0.06
0.22
0.25
0.25
0.28
growth rate 266.7% 13.6% 0.0% 12.0%
Earnings BIT 375.51
703.17
764.47
796.88
951.27
1,425.13
growth rate 87.3% 8.7% 4.2% 19.4% 49.8%
Avg.PE 16.86
14.92
18.12
15.25
growth rate -11.5% 21.5% -15.8%
ROA 6.04
5.64
9.54
8.13
7.09
9.17
12.72
11.45
10.97
9.83
9.21
growth rate -6.6% 69.2% -14.8% -12.8% 29.3% 38.7% -10.0% -4.2% -10.4% -6.3%
ROE 7.92
7.77
13.66
12.88
12.62
17.55
18.14
14.27
14.75
14.87
17.88
growth rate -1.9% 75.8% -5.7% -2.0% 39.1% 3.4% -21.3% 3.4% 0.8% 20.2%
ROIC 6.26
7.07
12.02
11.00
10.49
13.06
15.99
13.17
12.32
11.33
11.87
growth rate 12.9% 70.0% -8.5% -4.6% 24.5% 22.4% -17.6% -6.5% -8.0% 4.8%
Cur. Ratio 2.17
3.22
2.27
1.95
1.04
1.27
3.97
4.85
2.22
1.72
1.06
growth rate 48.4% -29.5% -14.1% -46.7% 22.1% 212.6% 22.2% -54.2% -22.5% -38.4%
Quick Ratio 1.76
2.52
1.93
1.71
0.89
0.94
3.52
4.28
1.81
1.46
0.79
growth rate 43.2% -23.4% -11.4% -48.0% 5.6% 274.5% 21.6% -57.7% -19.3% -45.9%
Leverage 1.46
1.30
1.54
1.62
1.92
1.91
1.25
1.25
1.43
1.59
2.25
growth rate -11.0% 18.5% 5.2% 18.5% -0.5% -34.6% 0.0% 14.4% 11.2% 41.5%
Balance Sheet Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 876.92
952.45
1,272.13
1,546.83
1,489.93
1,633.06
growth rate 8.6% 33.6% 21.6% -3.7% 9.6%
Acct.Payable 69.37
59.04
83.22
116.14
104.60
279.75
growth rate -14.9% 40.9% 39.6% -9.9% 167.5%
Cur.Assets 1,652.37
3,525.96
5,071.44
5,282.46
6,295.93
8,675.31
growth rate 113.4% 43.8% 4.2% 19.2% 37.8%
Total Assets 3,387.46
6,130.76
7,052.92
9,205.85
10,760.40
17,538.81
growth rate 81.0% 15.0% 30.5% 16.9% 63.0%
Cash 333.15
151.86
843.67
397.78
1,265.87
1,672.87
growth rate -54.4% 455.6% -52.9% 218.2% 32.2%
Inventory 234.73
251.20
285.61
452.67
420.36
585.61
growth rate 7.0% 13.7% 58.5% -7.1% 39.3%
Cur.Liabilities 1,302.98
888.24
1,045.43
2,374.78
3,654.80
8,202.93
growth rate -31.8% 17.7% 127.2% 53.9% 124.4%
Liabilities 1,489.77
1,093.20
1,253.39
2,643.85
3,864.48
9,604.78
growth rate -26.6% 14.7% 110.9% 46.2% 148.5%
LT Debt 8.59
847.51
growth rate 150.5%
Equity 1,769.04
4,907.60
5,663.96
6,428.54
6,768.40
7,808.41
growth rate 177.4% 15.4% 13.5% 5.3% 15.4%
Common Shares 492.00
493.00
493.00
493.00
493.00
493.00
2,995.00
3,321.00
3,321.00
3,259.00
3,222.00
growth rate 0.2% 0.0% 0.0% 0.0% 0.0% 507.5% 10.9% 0.0% -1.9% -1.1%
Cash Flow Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 265.02
268.84
204.11
263.41
507.32
728.17
growth rate 1.4% -24.1% 29.1% 92.6% 43.5%
Cash Dividends 106.98
106.98
106.98
106.98
212.63
289.72
growth rate 0.0% 0.0% 0.0% 98.8% 36.3%
Cash From OA 438.62
494.57
394.71
592.03
964.10
1,045.59
growth rate 12.8% -20.2% 50.0% 62.9% 8.5%
FCF per Share 0.03
0.01
0.02
0.02
growth rate -42.3% 100.0% 0.0%
Sale Purchase of Stock 3,139.34
3,139.34
2.71
2.71
2.71
growth rate 0.0% -99.9% 0.0% 0.0%
FCF 125.00
62.00
139.00
114.00
-13.00
168.00
30.00
187.00
273.00
339.00
-1,439.00
growth rate -50.4% 124.2% -18.0% -100.0% 100.0% -82.1% 523.3% 46.0% 24.2% -100.0%
Income Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 2,515.11
2,543.99
2,563.13
2,917.79
3,814.84
5,173.39
growth rate 1.2% 0.8% 13.8% 30.7% 35.6%
Op.Income 375.51
703.17
764.47
796.88
951.27
1,425.13
growth rate 87.3% 8.7% 4.2% 19.4% 49.8%
IBT 383.17
725.51
898.13
974.72
1,116.32
1,473.47
growth rate 89.4% 23.8% 8.5% 14.5% 32.0%
Net Income 310.50
605.52
754.52
891.54
981.37
1,303.37
growth rate 95.0% 24.6% 18.2% 10.1% 32.8%
EPS 0.12
0.13
0.25
0.28
0.31
0.63
0.20
0.23
0.27
0.30
0.40
growth rate 8.3% 92.3% 12.0% 10.7% 103.2% -68.3% 15.0% 17.4% 11.1% 33.3%
Gross Profit 2,101.61
2,061.48
2,087.41
2,382.75
2,963.36
4,049.41
growth rate -1.9% 1.3% 14.2% 24.4% 36.7%

Quarterly Statements

Item Name Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Earnings BIT 265.79
304.87
304.87
407.70
407.70
growth rate 14.7% 0.0% 33.7% 0.0%
Balance Sheet Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Acct.Receivable 1,489.93
1,517.66
1,517.66
1,633.06
1,633.06
growth rate 1.9% 0.0% 7.6% 0.0%
Acct.Payable 104.60
132.82
132.82
279.75
279.75
growth rate 27.0% 0.0% 110.6% 0.0%
Cur.Assets 6,295.93
7,853.44
7,853.44
8,675.31
8,675.31
growth rate 24.7% 0.0% 10.5% 0.0%
Total Assets 10,760.40
16,157.00
16,157.00
17,538.81
17,538.81
growth rate 50.2% 0.0% 8.6% 0.0%
Cash 1,265.87
1,795.54
1,795.54
1,672.87
1,672.87
growth rate 41.8% 0.0% -6.8% 0.0%
Inventory 420.36
529.25
529.25
585.61
585.61
growth rate 25.9% 0.0% 10.7% 0.0%
Cur.Liabilities 3,654.80
6,781.51
6,781.51
8,202.93
8,202.93
growth rate 85.6% 0.0% 21.0% 0.0%
Liabilities 3,864.48
8,829.39
8,829.39
9,604.78
9,604.78
growth rate 128.5% 0.0% 8.8% 0.0%
LT Debt 847.51
847.51
growth rate 0.0%
Equity 6,768.40
7,199.59
7,199.59
7,808.41
7,808.41
growth rate 6.4% 0.0% 8.5% 0.0%
Common Shares 427.27
421.34
421.34
421.34
421.34
growth rate -1.4% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Capital Expenditures 253.66
364.08
364.08
364.08
364.08
growth rate 43.5% 0.0% 0.0% 0.0%
Cash Dividends 106.31
74.50
74.50
70.36
70.36
growth rate -29.9% 0.0% -5.6% 0.0%
Cash From OA 335.49
187.64
187.64
335.16
335.16
growth rate -44.1% 0.0% 78.6% 0.0%
Sale Purchase of Stock 1.35
growth rate
FCF 81.83
-176.45
-176.45
-28.93
-28.93
growth rate -100.0% 0.0% 0.0% 0.0%
Income Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Sales 982.03
1,101.89
1,101.89
1,484.81
1,484.81
growth rate 12.2% 0.0% 34.8% 0.0%
Op.Income 265.79
304.87
304.87
407.70
407.70
growth rate 14.7% 0.0% 33.7% 0.0%
IBT 327.58
337.03
337.03
399.71
399.71
growth rate 2.9% 0.0% 18.6% 0.0%
Net Income 298.00
281.44
281.44
370.25
370.25
growth rate -5.6% 0.0% 31.6% 0.0%
Gross Profit 768.49
878.25
878.25
1,146.46
1,146.46
growth rate 14.3% 0.0% 30.5% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

C (63.78)

YOY Growth Grade:

B (67.87)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 11.37 11.45
EPS / Growth 0.06

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 16.8%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 16.8% 16.8% 16.8%
Future PE 0.01 7.58 14.96
Future EPS 0.26 0.26 0.26
Value Price
MOS %
0.00
-99.9%
0.49
-23.0%
0.96
51.9%
MOS Price 0.00 0.24 0.48
IRT 6.26 6.26 6.26

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.